Cheryl Blanchard

Cheryl Renee Blanchard is currently President, Chief Executive Officer & Director at ArthroSurface, Inc. Executive Chairman at Anika Therapeutics, Inc. since 2026.
Director at Massachusetts Biotechnology Council since 2018, Elute, Inc. since 2013, Lumicell, Inc., Surgicure Technologies, Inc., and National Academy of Engineering.
President & Manager at Parcus Medical LLC.
Director at Xilio Therapeutics, Inc. and Clarevia Ventures starting in 2026.
Former roles include President, Chief Executive Officer & Director at Microchips Biotech, Inc. (2014–2019), President & Chief Executive Officer at Keratin Biosciences, Inc. (2018–2019), President & Chief Executive Officer at Daré MBI, Inc., Director at Neuronetics, Inc. (2019–2020), Director at Novum Medical, Inc., Independent Director at SeaSpine Holdings Corp.
(2015–2019), Director at ISTO Technologies, Inc., Independent Director at Vigil Neuroscience, Inc. (2020–2025), Independent Director at Daré Bioscience, Inc. (2019–2024), Chief Scientific Officer at Zimmer Biomet Holdings, Inc. (2000–2011), Member-Supervisory Board at CeramTec GmbH, Manager at Oak Ridge National Laboratory, Manager at Southwest Research Institute (1986–2000), Chief Scientific Officer & Senior Vice President at Zimmer, Inc. (2000–2012), Professor at the University of Texas Health Center and the University of Texas at San Antonio, Manager at Texas University of Health Center at San Antonio, and Principal at Blanchard Consulting LLC (2012–2020).
Education includes undergraduate degree from Alfred University (1986), graduate and doctorate degrees from The University of Texas at Austin (1989 and 1993).